Yukinori Ozaki
Breast Medical Oncology Cancer Institute Hospital, Japan Foundation for Cancer Research
Seminars
Tuesday 19th May 2026
Development & Clinical Validation of a ctDNA-Based MRD Assay in Breast Cancer
5:00 pm
- MRD detection using ctDNA represents a promising approach for early relapse prediction in breast cancer
- Observational studies showed MRD is a strong prognostic factor consistently across the subtypes and clinical situations
- Interventional MRD-guided trials are now reshaping treatment paradigms
